{"title":"不同尺寸DPP-4抑制剂的研究","authors":"T. Mughal","doi":"10.33590/emjdiabet/10310228","DOIUrl":null,"url":null,"abstract":"This Takeda-sponsored European Association for the Study of Diabetes (EASD) symposium addressed the pharmacology, clinical use, and future therapeutic application of dipeptidyl-peptidase-4 (DPP-4) inhibitors. The scientific programme covered the clinical efficacy of DPP-4 inhibitors, their durability in clinical practice, and their use in combination therapy with other antidiabetic drugs. The important issue of the effect of this class of drugs on cardiovascular (CV) outcomes was also explored. The symposium was chaired by Prof Heinz Drexel and included insightful talks from an expert faculty comprising of Profs Jørgen Rungby, Jochen Seufert, and Kausik Ray.","PeriodicalId":418035,"journal":{"name":"EMJ Diabetes","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigating the Different Dimensions of DPP-4 Inhibitors\",\"authors\":\"T. Mughal\",\"doi\":\"10.33590/emjdiabet/10310228\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This Takeda-sponsored European Association for the Study of Diabetes (EASD) symposium addressed the pharmacology, clinical use, and future therapeutic application of dipeptidyl-peptidase-4 (DPP-4) inhibitors. The scientific programme covered the clinical efficacy of DPP-4 inhibitors, their durability in clinical practice, and their use in combination therapy with other antidiabetic drugs. The important issue of the effect of this class of drugs on cardiovascular (CV) outcomes was also explored. The symposium was chaired by Prof Heinz Drexel and included insightful talks from an expert faculty comprising of Profs Jørgen Rungby, Jochen Seufert, and Kausik Ray.\",\"PeriodicalId\":418035,\"journal\":{\"name\":\"EMJ Diabetes\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emjdiabet/10310228\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjdiabet/10310228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Investigating the Different Dimensions of DPP-4 Inhibitors
This Takeda-sponsored European Association for the Study of Diabetes (EASD) symposium addressed the pharmacology, clinical use, and future therapeutic application of dipeptidyl-peptidase-4 (DPP-4) inhibitors. The scientific programme covered the clinical efficacy of DPP-4 inhibitors, their durability in clinical practice, and their use in combination therapy with other antidiabetic drugs. The important issue of the effect of this class of drugs on cardiovascular (CV) outcomes was also explored. The symposium was chaired by Prof Heinz Drexel and included insightful talks from an expert faculty comprising of Profs Jørgen Rungby, Jochen Seufert, and Kausik Ray.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
